Lisa Bonadonna

Following her PhD in Immunology at the University of Melbourne, Lisa Bonadonna entered the pharmaceutical industry holding a range of senior medical, research, commercial and global health positions covering many geographies. As Vice President of the Adult Vaccine Portfolio, she co-led GSK’s Vaccines H1N1 pandemic response and subsequently negotiated the first industry agreement signed with the WHO under the Pandemic Influenza Preparedness Framework. Dr Bonadonna has an MBA and an MSc in Health Policy, Programming & Financing, the latter incorporating a dissertation on access to medicines. In 2021 Lisa joined the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute her expertise in tackling the COVID-19 pandemic with a particular focus on Africa. More recently Lisa had been working with South Africa’s Aspen Pharmacare assisting with their foray into biologicals and vaccines and has now taken up a director’s role with the newly established Cumming Centre for Pandemic Therapeutics, at her alma mater. Lisa is on the Board of the African Vaccine Manufacturing Initiative and is an active member of organisation’s Market Shaping and Resource Mobilisation Working Groups.